Initially two different classes of rewriteable optical storage media have been commercialized, namely magneto-optical and phase-change media. In recent years, however, most rewriteable products ...

Bayer has added another phase 3 trial into its registration programme for oral Factor XIa inhibitor asundexian, signalling growing confidence in a drug that generated mixed results in phase 2.

A drug billed by Sanofi as a successor to its blockbuster inflammation and immunology blockbuster Dupixent is being prepared for phase 3 trials in asthma – even though it missed the mark in a ...

Ironheart's release has been long overdue. Originally conceived as a movie, the Marvel Phase 5 project was turned into a TV production in December 2020 – a developmental shift that came almost ...